SGMS2 increased the expression of TGF-β1 by upregulating SM, which subsequently activated the TGF-β/Smad signalling pathway and promoted EMT in breast cancer cells, thus increasing the migration and invasiveness of breast cancer cells. This evidence concerns the gene TGFB1 and breast cancer.